Taken together, this underlies the potential of a CD133-targeted therapy, particularly in MLL-AF4 ALL, which accounts for 5–10% of all B-ALL patients that have a particularly poor prognosis [23,37,38]. The gene discussed is PROM1; the disease is precursor B-cell acute lymphoblastic leukemia.